214 results match your criteria lusc luad

Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients.

Sci Rep 2021 Apr 7;11(1):7633. Epub 2021 Apr 7.

DiaCarta, Inc., 2600 Hilltop Drive, Richmond, CA, 94806, USA.

Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate the utility of plasma cell-free DNA (cfDNA) as a prognostic biomarker and efficacy predictor of chemotherapy (CT) with or without these precision therapies in NSCLC patients. Peripheral cfDNA levels in 154 NSCLC patients were quantified before and after the first target cycle of chemotherapy. Read More

View Article and Full-Text PDF

Differential expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.

Oncol Rep 2021 May 31;45(5). Epub 2021 Mar 31.

Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, P.R. China.

Disruption in mucins (MUCs) is involved in cancer development and metastasis and is thus used as a biomarker. Non‑small cell lung carcinoma (NSCLC) is characterized by heterogeneous genetic and epigenetic alterations. Lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are the two primary subtypes of NSCLC that require different therapeutic interventions. Read More

View Article and Full-Text PDF

Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.

Front Immunol 2021 25;12:598671. Epub 2021 Feb 25.

Precision Medicine Center, Seoul National University Bundang Hospital, Seongnamsi, South Korea.

Non-small-cell lung cancers (NSCLCs) are largely classified into lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which have different therapeutic options according to its molecular profiles and immune checkpoint expression, especially PD-L1, which is a suppressive factor in the tumor microenvironment. The tumor microenvironment can be altered by the genomic mutations on specific innate immune genes as well as tumor suppressor genes, so it is essential to comprehend the association between tumor microenvironment and tumor suppressor genes to discover the promising immunotherapeutic strategy to overcome the resistance of immune check point blockade. In this study, we aimed to analyze how the somatic mutations in tumor suppressor genes affect the tumor immune microenvironment through a comprehensive analysis of mutational profiling on the representative tumor suppressor genes (, ) and immune gene expression in The Cancer Genome Atlas (TCGA) 155 lung squamous cell carcinoma (LUSC) and 196 lung adenocarcinoma (LUAD) samples. Read More

View Article and Full-Text PDF
February 2021

Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.

J Pers Med 2021 Feb 23;11(2). Epub 2021 Feb 23.

Department of Bioinformatics, Muğla Sıtkı Koçman University, 48000 Muğla, Turkey.

Lung cancer is the second most frequently diagnosed cancer type and responsible for the highest number of cancer deaths worldwide. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are subtypes of non-small-cell lung cancer which has the highest frequency of lung cancer cases. We aimed to analyze genomic and transcriptomic variations including simple nucleotide variations (SNVs), copy number variations (CNVs) and differential expressed genes (DEGs) in order to find key genes and pathways for diagnostic and prognostic prediction for lung adenocarcinoma and lung squamous cell carcinoma. Read More

View Article and Full-Text PDF
February 2021

Females and Males Show Differences in Early-Stage Transcriptomic Biomarkers of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.

Diagnostics (Basel) 2021 Feb 19;11(2). Epub 2021 Feb 19.

College of Computer Science and Technology, Jilin University, Changchun 130012, China.

The incidence and mortality rates of lung cancers are different between females and males. Therefore, sex information should be an important part of how to train and optimize a diagnostic model. However, most of the existing studies do not fully utilize this information. Read More

View Article and Full-Text PDF
February 2021

Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.

Oncol Lett 2021 Apr 3;21(4):249. Epub 2021 Feb 3.

Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.

The determination of biomarkers in the blood specific for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is crucial for the selection of effective treatment strategies and the prediction of prognosis. The purpose of the present study was to analyze the differentially expressed genes (DEGs) in LUSC and LUAD from The Cancer Genome Atlas (TCGA) database. In order to identify the potential biomarkers for non-small cell lung cancer (NSCLC) for clinical diagnosis, bioinformatics was used to analyze the DEGs of two subtypes of NSCLC, LUAD and LUSC. Read More

View Article and Full-Text PDF

Identification of Primary and Metastatic Lung Cancer-Related lncRNAs and Potential Targeted Drugs Based on ceRNA Network.

Front Oncol 2020 3;10:628930. Epub 2021 Feb 3.

College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.

Lung cancer metastasis is the leading cause of poor prognosis and death for patients. Long noncoding RNAs (lncRNAs) have been validated the close correlation with lung cancer metastasis, but few comprehensive analyses have reported the specific association between lncRNA and cancer metastasis, especially both competing endogenous RNA (ceRNA) regulatory relationships and functional regulatory networks. Here, we constructed primary and metastatic ceRNA networks, identified 12 and 3 candidate lncRNAs for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) respectively and excavated some drugs that might have potential therapeutic effects on lung cancer progression. Read More

View Article and Full-Text PDF
February 2021

Downregulation of CISD2 Has Prognostic Value in Non-Small Cell Lung Cancer and Inhibits the Tumorigenesis by Inducing Mitochondrial Dysfunction.

Front Oncol 2020 1;10:595524. Epub 2021 Feb 1.

Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.

CISD2, a NEET protein that coordinates 2Fe-2S clusters through its CDGSH domain, is critical for normal development and iron homeostasis. CISD2 plays an important role in Fe-S cluster transfer and promotes cancer proliferation. However, its specific role in the development of non-small cell lung cancer (NSCLC) remains unclear. Read More

View Article and Full-Text PDF
February 2021

Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes.

Curr Res Microb Sci 2021 Dec 9;2:100022. Epub 2021 Feb 9.

Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali 3814, Bangladesh.

Coronavirus disease-2019 (COVID-19) is a recent world pandemic disease that is caused by a newly discovered strain of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS- CoV-2). Patients with comorbidities are most vulnerable to this disease. Therefore, cancer patients are reported to be more susceptible to COVID-19 infection, particularly lung cancer patients. Read More

View Article and Full-Text PDF
December 2021

Pan-Cancer Molecular Characterization of mA Regulators and Immunogenomic Perspective on the Tumor Microenvironment.

Front Oncol 2020 28;10:618374. Epub 2021 Jan 28.

Department of Urology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Purpose: N6-methyladenosine (mA) methylation plays a critical role in diverse biological processes. However, knowledge regarding the constitution of mA on tumor microenvironment (TME) and tumor-infiltrating lymphocytes (TILs) across cancer types is still lacking. We performed comprehensive immuno-genomic analyses to reveal molecular characterization of the mA regulators and immune-related genes (IRGs) across TME and TIL heterogeneity. Read More

View Article and Full-Text PDF
January 2021

CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.

Pulm Pharmacol Ther 2021 Apr 11;67:102001. Epub 2021 Feb 11.

The Third Department of Respiratory Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China. Electronic address:

Objective: CXCR1, a member of the seven-transmembrane chemokine receptor family, promotes cell proliferation and metastasis in many tumors. The present study was undertaken to explore the interrelation between CXCR1 expression and the prognosis of advanced non-small cell lung cancer (NSCLC) in addition to the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma (LUAD).

Methods: The expression of CXCR1 in NSCLC tissues was assessed by immunohistochemistry. Read More

View Article and Full-Text PDF

TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation.

Biol Chem 2021 Feb 19. Epub 2021 Feb 19.

School of Life Sciences, Zhengzhou University, Zhengzhou450001, China.

Long non-coding RNAs (lncRNAs) are involved in the occurrence and development of human cancers including lung adenocarcinoma (LUAD). SLC2A1-AS1 is a novel lncRNA that has been reported to be exceptionally expressed in several cancer types. However, the expression and role of SLC2A1-AS1 in cancer remains largely unclear. Read More

View Article and Full-Text PDF
February 2021

Investigation on Potential Correlation Between Small Nuclear Ribonucleoprotein Polypeptide A and Lung Cancer.

Front Genet 2020 21;11:610704. Epub 2021 Jan 21.

Department of Thoracic Surgery, Linyi Central Hospital, Linyi, China.

(small nuclear ribonucleoprotein polypeptide A) gene is essential for the pre-mRNA splicing process. Using the available datasets of TCGA or GEO, we aimed at exploring the potential association between the gene and lung cancer by several online tools (such as GEIPA2, MEXPRESS, Oncomine) and bioinformatics analysis software (R or GSEA). was highly expressed in the tissues of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma tissue (LUSC), compared with control tissues. Read More

View Article and Full-Text PDF
January 2021

A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.

Kai Yang Ying Wu

BMC Cancer 2021 Feb 6;21(1):128. Epub 2021 Feb 6.

Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, 510080, China.

Background: Early-stage non-small cell lung carcinoma (NSCLC) accounts for more than 80% of lung cancer, which is a kind of cancer with high heterogeneity, so the genetic heterogeneity and molecular subtype should be explored.

Methods: Partitioning Around Medoid algorithm was used to acquire the molecular subtype for early-stage NSCLC based on prognosis-related mRNAs and methylation sites. Random forest (RF) and support vector machine (SVM) were used to build prediction models for subtypes. Read More

View Article and Full-Text PDF
February 2021

Plakophilin-2 Promotes Lung Adenocarcinoma Development via Enhancing Focal Adhesion and Epithelial-Mesenchymal Transition.

Cancer Manag Res 2021 22;13:559-570. Epub 2021 Jan 22.

Medical Oncology Department of Thoracic Cancer (2), Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, Liaoning, People's Republic of China.

Background: Lung cancer is one of the most aggressive tumors with high incidence and mortality, which could be classified into lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Overexpression of Plakophilin-2 (PKP2) has been reported in multiple malignancies. However, the expression and function mechanism of PKP2 in LUAD remain illusive. Read More

View Article and Full-Text PDF
January 2021

Predicting potential residues associated with lung cancer using deep neural network.

Mutat Res 2020 Dec 11;822:111737. Epub 2020 Dec 11.

Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, 600036, India; School of Computing, Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Midori-ku, Kanagawa, 226-8503, Yokohama, Japan. Electronic address:

Lung cancer is a prominent type of cancer, which leads to high mortality rate worldwide. The major lung cancers lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) occur mainly due to somatic driver mutations in proteins and screening of such mutations is often cost and time intensive. Hence, in the present study, we systematically analyzed the preferred residues, residues pairs and motifs of 4172 disease prone sites in 195 proteins and compared with 4137 neutral sites. Read More

View Article and Full-Text PDF
December 2020

Exploring the mechanism of aidi injection for lung cancer by network pharmacology approach and molecular docking validation.

Biosci Rep 2021 Feb;41(2)

Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.

Background: Aidi injection (ADI) is an effective Traditional Chinese medicine preparation widely used for lung cancer. However, the pharmacological mechanisms of ADI on lung cancer remain to be elucidated.

Methods: A network pharmacology (NP)-based approach and the molecular docking validation were conducted to explore underlying mechanisms of ADI on lung cancer. Read More

View Article and Full-Text PDF
February 2021

The landscape of kinase domain duplication in Chinese lung cancer patients.

Ann Transl Med 2020 Dec;8(24):1642

Department of Medical Oncology, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.

Background: Kinase domain duplication (KDD) is a special type of large genomic rearrangement (LGR), occurring in the kinase domain of protein kinase genes. KDD of some lung cancer driver genes, such as.

Egfr: KDD, has been identified and implicated to be oncogenic in non-small cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF
December 2020

Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer.

Thorac Cancer 2021 03 21;12(5):659-666. Epub 2021 Jan 21.

Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Background: Despite the emerging insights into many snoRNAs (small nucleolar RNAs) which are detectable in body fluids and serve as noninvasive biomarkers, few studies have previously discussed the role of snoRNAs in tumor-educated platelets (TEPs). Herein, we systematically estimated dysregulation of snoRNAs in non-small cell lung cancer (NSCLC) and clarified the biomarker potential of SNORD55 in platelets.

Methods: We compared expression of snoRNAs between NSCLC and normal tissues using SNORic datasets. Read More

View Article and Full-Text PDF

Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients.

Mol Oncol 2020 11 3;14(11):2759-2774. Epub 2020 Sep 3.

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. Significant CpG probes were confirmed in 617 samples from The Cancer Genome Atlas. Read More

View Article and Full-Text PDF
November 2020

Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses.

Signal Transduct Target Ther 2021 Jan 8;6(1). Epub 2021 Jan 8.

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, No. 37, Guo Xue Alley, 610041, Chengdu, Sichuan, China.

Primary pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) subtype. Clinical features have been described in our previous report, but molecular characteristics remain unclear. Herein, pLELC genomic features were explored. Read More

View Article and Full-Text PDF
January 2021

Identification of four methylation-driven genes as candidate biomarkers for monitoring single-walled carbon nanotube-induced malignant transformation of the lung.

Toxicol Appl Pharmacol 2021 Feb 31;412:115391. Epub 2020 Dec 31.

State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and Engineering, Donghua University, Shanghai 201620, China. Electronic address:

Long-term exposure to carbon nanotubes (CNTs) has been reported to induce malignant transformation. This study aimed to screen candidate biomarkers for monitoring occupational workers to prevent the development of lung cancer. mRNA (GSE56104) and methylation (GSE153246) profiles of lung epithelial BEAS-2B cells exposed to malignant transformation dose of single-walled CNTs or control medium were downloaded from Gene Expression Omnibus database. Read More

View Article and Full-Text PDF
February 2021

Identification of Potential Long Non-coding RNA Expression Quantitative Trait Methylations in Lung Adenocarcinoma and Lung Squamous Carcinoma.

Front Genet 2020 9;11:602035. Epub 2020 Dec 9.

Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin, China.

There are associations between DNA methylation and the expression of long non-coding RNA (lncRNA), also known as lncRNA expression quantitative trait methylations (lnc-eQTMs). Lnc-eQTMs may induce a wide range of carcinogenesis pathways. However, lnc-eQTMs have not been globally identified and studied, and their roles in lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) are largely unknown. Read More

View Article and Full-Text PDF
December 2020

GPR115 Contributes to Lung Adenocarcinoma Metastasis Associated With LAMC2 and Predicts a Poor Prognosis.

Front Oncol 2020 20;10:577530. Epub 2020 Nov 20.

Department of Respiratory Medicine, Affiliated Hospital of Nantong University, Nantong, China.

GPR115, a member of the adhesion G protein-coupled receptor family, is dysregulated in many cancers. However, the expression and function of GRP115 in non-small cell lung cancer (NSCLC) is not clear. Here, we examined the expression pattern, clinical significance, and function of GPR115 in NSCLC by analysis of clinical specimens and human cell lines and bioinformatics analysis. Read More

View Article and Full-Text PDF
November 2020

The Significance of Secreted Phosphoprotein 1 in Multiple Human Cancers.

Front Mol Biosci 2020 24;7:565383. Epub 2020 Nov 24.

Department of Thoracic Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, China.

Malignant tumor represents a major reason for death in the world and its incidence is growing rapidly. Developing the tools for early diagnosis is possibly a promising way to offer diverse therapeutic options and promote the survival chance. Secreted phosphoprotein 1 (SPP1), also called Osteopontin (OPN), has been demonstrated overexpressed in many cancers. Read More

View Article and Full-Text PDF
November 2020

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.

J Immunother Cancer 2020 12;8(2)

State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Background: Ephrin type-A receptors (EPHA) are members of family of receptor tyrosine kinases and are related to tumor immunogenicity and immune microenvironment, however, the association between mutation ( ) and efficacy of immune checkpoint inhibitors (ICIs) has not been investigated in non-small cell lung cancer (NSCLC).

Methods: Multiple cohorts were used to assess the immunotherapeutic predictive performance of , including one discovery cohort (n=79) and two public validation cohort (cohort 1: NSCLC, n=165; cohort 2: pan-cancer, n=1662). The Cancer Genome Atlas cohort was used for prognostic analysis and mechanism exploration. Read More

View Article and Full-Text PDF
December 2020

Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer.

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820971600

Department of Pulmonary and Critical Care Medicine, Cangzhou People's Hospital, Cangzhou, China.

Objective: This study aims to explore the clinical value of systemic chemotherapy combined with bronchoscopic seed implantation in advanced lung cancer treatment.

Methods: The study enrolled 253 patients with advanced lung cancer in Cangzhou People's Hospital from March 2018 to March 2020, and they were divided into test group and control group. Test group was given systemic chemotherapy combined with bronchoscopic seed implantation, while control group was given systemic chemotherapy. Read More

View Article and Full-Text PDF
December 2020

High expression of MYEOV reflects poor prognosis in non-small cell lung cancer.

Rui Zhang Aiqing Ma

Gene 2021 Feb 2;770:145337. Epub 2020 Dec 2.

Department of Operating Room, Linyi Tumor Hospital, Linyi City, Shandong Province, PR China. Electronic address:

Background: The myeloma overexpressed gene (MYEOV) plays a critical role in tumorigenesis in a variety of cancers. However, little is known of the prognosis and immune infiltration associated with MYEOV in non-small cell lung cancer (NSCLC).

Methods: We used several databases (Oncomine, TCGA, and GEO) to analysis the expression, prognosis, and immune infiltration, associated with MYEOV in NSCLC. Read More

View Article and Full-Text PDF
February 2021

Immune Escape Mechanisms in Non Small Cell Lung Cancer.

Cancers (Basel) 2020 Dec 2;12(12). Epub 2020 Dec 2.

Human Tumors Immunobiology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy.

Development of strong immune evasion has been traditionally associated with the late stages of solid tumor progression, since advanced cancers are more likely to have reached the third phase of the immunoediting process. However, by integrating a variety of approaches, evidence for active immune escape mechanisms has been found even in the pre-invasive lesions that later progress to the main NSCLC histotypes. Pre-invasive lesions of adenocarcinoma (LUAD) and of squamous cell carcinoma (LUSC) can show impaired antigen presentation, loss of heterozygosity at the Human Leukocyte Antigen (HLA) region, neoantigen silencing, activation of immune checkpoints, altered TH1/TH2 cytokine ratios, and immune contexture evolution. Read More

View Article and Full-Text PDF
December 2020

Lung squamous cell carcinoma and lung adenocarcinoma differential gene expression regulation through pathways of Notch, Hedgehog, Wnt, and ErbB signalling.

Sci Rep 2020 12 3;10(1):21128. Epub 2020 Dec 3.

Department of Molecular Carcinogenesis, Medical University of Lodz, 90-752, Lodz, Poland.

Lung malignancies comprise lethal and aggressive tumours that remain the leading cancer-related death cause worldwide. Regarding histological classification, lung squamous cell carcinoma (LUSC) and adenocarcinoma (LUAD) account for the majority of cases. Surgical resection and various combinations of chemo- and radiation therapies are the golden standards in the treatment of lung cancers, although the five-year survival rate remains very poor. Read More

View Article and Full-Text PDF
December 2020